MREO实时信号 | 通过Getagraph.com最大化利润

购买 107628 min ago

@ $3.74

发出时间: 15 Feb 2024 @ 01:33

回报率: -26.74%

上一信号: Feb 15 - 00:06

上一信号: 出售

回报率: 0.00 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...

Stats
今日成交量	562 550
平均成交量	1.29M
市值	383.76M
EPS	$0 ( 2024-03-26 )
下一个收益日期	( $0 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.70
ATR14	$0.00500 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Ekblom Anders	Buy	45 000	Share Options (Right to buy)
2024-02-08	Ekblom Anders	Buy	19 471	Deferred Restricted Stock Units
2024-02-08	Jacquet Pierre	Buy	45 000	Share Options (Right to buy)
2024-02-08	Jacquet Pierre	Buy	15 553	Deferred Restricted Stock Units
2024-02-08	Yoskowitz Marc J	Buy	45 000	Share Options (Right to buy)

INSIDER POWER
-60.64
Last 97 transactions
Buy: 2 158 393 \| Sell: 9 188 547

音量相关性

長: 0.06 (neutral)

短: -0.90 (strong negative)

Signal:(26.447) Be Aware. Possible trading coming up! (swing)

Mereo BioPharma Group plc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Mereo BioPharma Group plc 相关性 - 货币/商品

0.31
( neutral )

0.06
( neutral )

0.00
( neutral )

0.29
( neutral )

-0.43
( neutral )

Mereo BioPharma Group plc 财务报表

Annual	2023
营收:	$10.00M
毛利润:	$7.43M (74.26 %)
EPS:	$0

FY	2023
营收:	$10.00M
毛利润:	$7.43M (74.26 %)
EPS:	$0

FY	2022
营收:	$1.51M
毛利润:	$571 000 (37.89 %)
EPS:	$-0.280

FY	2021
营收:	$36.46M
毛利润:	$18.56M (50.89 %)
EPS:	$0.159

Financial Reports:

No articles found.

Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.